Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5179881
Max Phase: Preclinical
Molecular Formula: C30H51N3O9
Molecular Weight: 597.75
Associated Items:
ID: ALA5179881
Max Phase: Preclinical
Molecular Formula: C30H51N3O9
Molecular Weight: 597.75
Associated Items:
Canonical SMILES: CCCCC[C@@H]1OC(=O)[C@@H](C)NC(=O)[C@H](CCCCC)OC(=O)[C@@H](C)NC(=O)[C@H](CCCCC)OC(=O)[C@@H](C)NC1=O
Standard InChI: InChI=1S/C30H51N3O9/c1-7-10-13-16-22-25(34)31-20(5)29(38)41-24(18-15-12-9-3)27(36)33-21(6)30(39)42-23(17-14-11-8-2)26(35)32-19(4)28(37)40-22/h19-24H,7-18H2,1-6H3,(H,31,34)(H,32,35)(H,33,36)/t19-,20-,21-,22+,23+,24+/m1/s1
Standard InChI Key: QMGQCGBVIXRFQO-JEYZWYLSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 597.75 | Molecular Weight (Monoisotopic): 597.3625 | AlogP: 2.99 | #Rotatable Bonds: 12 |
Polar Surface Area: 166.20 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.43 | CX Basic pKa: | CX LogP: 4.54 | CX LogD: 4.54 |
Aromatic Rings: 0 | Heavy Atoms: 42 | QED Weighted: 0.17 | Np Likeness Score: 0.69 |
1. Smith AN, Thorpe MP, Blackwell DJ, Batiste SM, Hopkins CR, Schley ND, Knollmann BC, Johnston JN.. (2022) Structure-Activity Relationships for the N-Me- Versus N-H-Amide Modification to Macrocyclic ent-Verticilide Antiarrhythmics., 13 (11.0): [PMID:36385927] [10.1021/acsmedchemlett.2c00377] |
Source(1):